Institut Godinot — Clinical Trial Site

109 Registered trials

69 Currently recruiting

Organisation

Institut Godinot

Location

Reims, France

Identifier

ORG-100045736

Address

1 Rue Du General Koenig, 51100, France

Departments

/
033016:
Centre d'oncologie
Clinical Research Unit
Département d’oncologie médicale
Department of Hematology and Medical Oncology
Digestive Oncology
gastroenterology
Hepato-gastroenterology
Hepatogastroenterology
Marne
médecine nucléaire
Medical Oncology
Medical oncology department
N/A
NA
Onco-Urology Department #1503
Oncologie
oncologie Digestive
Oncologie médicale
Oncologue
Oncology
oncology department
Oncology-Radiotherapy
Radiotherapist
Radiotherapy
Service d'hématologie et oncologie Médicale
Service d'Oncologie
Service d'oncologie médicale

Clinical trials at this site (109)

Search interface

ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene Recruiting

2025-522169-31-00 Adult Patients with HER2-IHC3+ selected solid cancers ( 4 2025-10-30
Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting

2025-520694-39-00 Metastatic or locally advanced irresectable (stage IV) 4 2025-10-24
SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal… Recruiting

2024-518358-17-00 Squamous cell carcinoma of the esophagus 4 2025-10-06
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 KRAS G12C-mutant, Locally Advanced Unresectable or Meta 5 2025-09-26
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
A Phase 1/2, open-label, multicenter, dose-escalation, and dose‑optimization study to evaluate the safety, tolerability, and activity of EIK… Recruiting

2024-520395-99-00 Advanced solid tumors 7 2025-08-12
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing st… Recruiting

2022-501315-13-00 Patients with lateralised oropharyngeal, laryngeal and 5 2025-03-06
Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting

2023-505291-30-01 Triple Negative Breast Cancer with residual disease aft 4 2025-03-06
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-02-05
Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting

2023-509963-25-00 Fluoropyrimidine (FP)-naive patients with gastrointesti 4 2025-01-17
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting

2023-506350-21-00 Localized, resected, FIGO stage I (2018 classification) 4 2025-01-06
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Patients with pMMR/MSS metastatic adenocarcinoma of the 4 2024-12-10
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 4 2024-11-04
A Clinical Trial to Assess a New Anti-Cancer Treatment (called DSB2455) Given On Its Own in Patients with Advanced Malignancies Recruiting

2023-508805-26-00 patients with active brain metastases, where the primar 1 2024-10-23
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
tislelizUMaB in canceR patients with molEcuLar residuaL disease (UMBRELLA) Recruiting

2023-503316-33-00 patients with a positive status for molecular residual 5 2024-09-26